Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis. 2012

Shannon Cope, and Matthias Kraemer, and Jie Zhang, and Gorana Capkun-Niggli, and Jeroen P Jansen
MAPI Consultancy, Boston, MA 02114, USA.

BACKGROUND The purpose of this study was to update our network meta-analysis in order to compare the efficacy of indacaterol 75 μg with that of a fixed-dose combination of formoterol and budesonide (FOR/BUD) and a fixed-dose combination salmeterol and fluticasone (SAL/FP) for the treatment of chronic obstructive pulmonary disease (COPD) based on evidence identified previously in addition to two new randomized clinical trials. METHODS Fifteen randomized, placebo-controlled clinical trials including COPD patients were evaluated: indacaterol 75 μg once daily (n = 2 studies), indacaterol 150 μg once daily (n = 5), indacaterol 300 μg once daily (n = 4), FOR/BUD 9/160 μg twice daily (n = 2), FOR/BUD 9/320 μg twice daily (n = 2), SAL/FP 50/500 μg twice daily (n = 4), and SAL/FP 50/250 μg twice daily (n = 1). All trials were analyzed simultaneously using a Bayesian network meta-analysis and relative treatment effects between all regimens were obtained. Treatment-by-covariate interactions were included where possible to improve the similarity of the trials. Outcomes of interest were trough forced expiratory volume in 1 second (FEV(1)) and transitional dyspnea index at 12 weeks. RESULTS Based on the results without adjustment for covariates, indacaterol 75 μg resulted in a greater improvement in FEV(1) at 12 weeks compared with FOR/BUD 9/160 μg (difference in change from baseline 0.09 L [95% credible interval 0.04-0.13]) and FOR/BUD 9/320 μg (0.07 L [0.03-0.11]) and was comparable with SAL/FP 50/250 μg (0.00 L [-0.07-0.07]) and SAL/FP 50/500 μg (0.01 L [-0.04-0.05]). For transitional dyspnea index, data was available only for indacaterol 75 μg versus SAL/FP 50/500 μg (-0.49 points [-1.87-0.89]). CONCLUSIONS Based on results of a network meta-analysis with and without covariates, indacaterol 75 μg is expected to be at least as efficacious as FOR/BUD (9/320 μg and 9/160 μg) and comparable with SAL/FP (50/250 μg and 50/500 μg) in terms of lung function. In terms of breathlessness (transitional dyspnea index) at 12 weeks, the results are inconclusive given the limited data.

UI MeSH Term Description Entries
D007189 Indans Aryl CYCLOPENTANES that are a reduced (protonated) form of INDENES. Indanones
D001993 Bronchodilator Agents Agents that cause an increase in the expansion of a bronchus or bronchial tubes. Bronchial-Dilating Agents,Bronchodilator,Bronchodilator Agent,Broncholytic Agent,Bronchodilator Effect,Bronchodilator Effects,Bronchodilators,Broncholytic Agents,Broncholytic Effect,Broncholytic Effects,Agent, Bronchodilator,Agent, Broncholytic,Agents, Bronchial-Dilating,Agents, Bronchodilator,Agents, Broncholytic,Bronchial Dilating Agents,Effect, Bronchodilator,Effect, Broncholytic,Effects, Bronchodilator,Effects, Broncholytic
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004417 Dyspnea Difficult or labored breathing. Orthopnea,Platypnea,Recumbent Dyspnea,Rest Dyspnea,Trepopnea,Breathlessness,Shortness of Breath,Breath Shortness,Dyspnea, Recumbent,Dyspnea, Rest,Dyspneas, Rest
D004983 Ethanolamines AMINO ALCOHOLS containing the ETHANOLAMINE; (-NH2CH2CHOH) group and its derivatives. Aminoethanols
D005541 Forced Expiratory Volume Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity. Forced Vital Capacity, Timed,Timed Vital Capacity,Vital Capacity, Timed,FEVt,Capacities, Timed Vital,Capacity, Timed Vital,Expiratory Volume, Forced,Expiratory Volumes, Forced,Forced Expiratory Volumes,Timed Vital Capacities,Vital Capacities, Timed,Volume, Forced Expiratory,Volumes, Forced Expiratory
D005938 Glucocorticoids A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. Glucocorticoid,Glucocorticoid Effect,Glucorticoid Effects,Effect, Glucocorticoid,Effects, Glucorticoid
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068297 Fluticasone-Salmeterol Drug Combination A drug combination of fluticasone and salmeterol that is used as an inhaler formulation to manage the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE. Advair,Advair Diskus,Advair HFA,Fluticasone - Salmeterol,Fluticasone Propionate - Salmeterol,Fluticasone Propionate - Salmeterol Combination,Fluticasone Propionate - Salmeterol Xinafoate,Fluticasone Propionate, Salmeterol Xinafoate Drug Combination,Fluticasone Propionate-Salmeterol Drug Combination,Fluticasone Propionate-Salmeterol Xinafoate Combination,Fluticasone Propionate-Salmeterol Xinafoate Drug Combination,Fluticasone-Salmeterol Combination,Seretide,Combination, Fluticasone-Salmeterol,Drug Combination, Fluticasone-Salmeterol,Fluticasone Propionate Salmeterol,Fluticasone Propionate Salmeterol Combination,Fluticasone Propionate Salmeterol Drug Combination,Fluticasone Propionate Salmeterol Xinafoate,Fluticasone Propionate Salmeterol Xinafoate Combination,Fluticasone Propionate Salmeterol Xinafoate Drug Combination,Fluticasone Salmeterol,Fluticasone Salmeterol Combination,Fluticasone Salmeterol Drug Combination

Related Publications

Shannon Cope, and Matthias Kraemer, and Jie Zhang, and Gorana Capkun-Niggli, and Jeroen P Jansen
January 2011, International journal of chronic obstructive pulmonary disease,
Shannon Cope, and Matthias Kraemer, and Jie Zhang, and Gorana Capkun-Niggli, and Jeroen P Jansen
May 2023, Thorax,
Shannon Cope, and Matthias Kraemer, and Jie Zhang, and Gorana Capkun-Niggli, and Jeroen P Jansen
June 2016, The New England journal of medicine,
Shannon Cope, and Matthias Kraemer, and Jie Zhang, and Gorana Capkun-Niggli, and Jeroen P Jansen
January 2011, Journal of medical economics,
Shannon Cope, and Matthias Kraemer, and Jie Zhang, and Gorana Capkun-Niggli, and Jeroen P Jansen
July 2008, The Cochrane database of systematic reviews,
Shannon Cope, and Matthias Kraemer, and Jie Zhang, and Gorana Capkun-Niggli, and Jeroen P Jansen
December 2011, The Cochrane database of systematic reviews,
Shannon Cope, and Matthias Kraemer, and Jie Zhang, and Gorana Capkun-Niggli, and Jeroen P Jansen
December 2009, Clinical therapeutics,
Shannon Cope, and Matthias Kraemer, and Jie Zhang, and Gorana Capkun-Niggli, and Jeroen P Jansen
December 2021, Journal of comparative effectiveness research,
Shannon Cope, and Matthias Kraemer, and Jie Zhang, and Gorana Capkun-Niggli, and Jeroen P Jansen
October 2016, The European respiratory journal,
Shannon Cope, and Matthias Kraemer, and Jie Zhang, and Gorana Capkun-Niggli, and Jeroen P Jansen
January 2016, International journal of chronic obstructive pulmonary disease,
Copied contents to your clipboard!